News headlines about Enanta Pharmaceuticals (NASDAQ:ENTA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.6244590542211 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of equities research analysts have recently weighed in on ENTA shares. Robert W. Baird lifted their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, August 8th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $54.00 price target on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $38.00 price target (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $45.25.
Enanta Pharmaceuticals (NASDAQ ENTA) traded up $0.87 during mid-day trading on Friday, reaching $50.68. The company had a trading volume of 146,340 shares, compared to its average volume of 150,821. Enanta Pharmaceuticals has a fifty-two week low of $22.35 and a fifty-two week high of $50.89.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million for the quarter, compared to the consensus estimate of $8.08 million. During the same period in the previous year, the firm earned ($0.06) EPS. The business’s revenue for the quarter was down 46.3% on a year-over-year basis. equities analysts expect that Enanta Pharmaceuticals will post 0.97 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Enanta Pharmaceuticals (ENTA) Share Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/11/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-enanta-pharmaceuticals-enta-share-price.html.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.